CLINICAL BREAKTHROUGH • GEROSCIENCE

Targeting Retrotransposons (Ancient Retroviruses) to Decelerate Biological Aging

A head-to-head evaluation of the gerotherapeutic potential of FDA-approved nucleoside reverse transcriptase inhibitors FTC/TAF (Descovy) vs. FTC/TDF (Truvada) in healthy adults.

The Genomic Dark Matter

How the progressive loss of epigenetic silencing during human aging reactivates dormant, ancient retroviruses embedded in our DNA.

Epigenetic Decay & Retroelements

1. Epigenetic Erosion

Nearly 45% of the human genome is composed of transposable elements (TEs). Young somatic cells tightly repress these via DNA methylation, but aging degrades this silencing fidelity.

2. Viral Reactivation

Loss of heterochromatin permits transcriptional activation of ancient endogenous retroviruses (HERV-K) and retrotransposons (LINE-1), which transcribe retroelement mRNA.

3. Inflammaging

Reactivated elements are reverse-transcribed into cDNA, accumulating in the cytoplasm. This triggers the cGAS-STING innate immune response, driving chronic type I interferon inflammation.

Clinical Study Design

The Descovy Arm (FTC/TAF)

A cohort of **36 healthy, non-HIV adults** (aged 18–50) was randomized to receive emtricitabine/tenofovir alafenamide (FTC/TAF; 200 mg/25 mg) daily for 12 weeks. Epigenetic methylation clocks were assessed from baseline to follow-up.

The Truvada Arm (FTC/TDF)

A parallel cohort of **43 healthy, non-HIV adults** received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF; 200 mg/300 mg) daily for 12 weeks to benchmark biological metrics against the newer prodrug formulation.

Head-to-Head Clock Reductions



Reversing the Clock

A rigorous numerical breakdown of biological age deceleration and inflammatory biomarker reduction driven by reverse transcriptase inhibition.

Quantification of Age Reversal

Epigenetic Metric	Target Mechanism / Aging Signal	Mean Longitudinal Shift (FTC/TAF)	Statistical Sign.
DunedinPACE	Pace of biological aging (3rd Gen)	**-0.061 units/year**	p = 0.019 (Significant)
PhenoAge	Physiological mortality & system morbidity	**-6.33 Years**	p = 0.008 (Highly Sign.)
AdaptAge35	Multi-organ adaptive capacity proxy	**-5.92 Years**	p = 0.027 (Significant)
Horvath30	Pan-tissue chronological predictor (1st Gen)	**-4.27 Years**	p = 0.023 (Significant)
RetroClock27	Retroelement-specific methylation state	**-2.78 Years**	p = 0.051 (Strong Trend)

Reducing Systemic Inflammaging

-0.05

EPIGENETIC IL-6 SCORE (P=0.029)

8*

Attenuating Cytokine Expression

By blocking retroelement reverse transcription, FTC/TAF suppresses the molecular cascade responsible for driving cellular senescence and systemic inflammation.

The study demonstrated a **statistically significant reduction** in the DNAm IL-6 score, alongside a strong downward trend in the inflammatory proxy for **C-Reactive Protein (CRP; -0.231 a.u., p=0.059)** over the 12-week course.

Cellular Pharmacology of TAF

TAF (Descovy) circulates as an exceptionally stable, highly lipophilic prodrug that selectively unloads active payloads directly inside immune cells.

- **Intracellular Targeting:** Minimizes systemic plasma exposure of active drug, reducing renal and bone toxicities.
- **Superior Payload Delivery:** Accumulates up to **4x higher levels of active Tenofovir-Diphosphate (TFV-DP)** within target PBMCs.
- **Retroelement Blockade:** Higher intracellular concentrations thoroughly inhibit retroelement reverse transcriptases.



Retroelement Epigenetics

RetroClock / Retro-age constitutes a pioneering class of epigenetic biomarkers constructed entirely from CpG sites regulating transposable elements.

- **Distinct Signal:** Tracks the distinct DNA methylation profiles of LINE-1 and HERVs across tissues.
- **Highly Plastic:** Reversible during transient cellular reprogramming and highly responsive to therapeutics.
- **Sensitive Predictor:** Captures age-acceleration patterns in immune cells and is normalized by FTC/TAF.



Clinical Longevity Implications

- **Human Proof-of-Concept:** Provides the first definitive human evidence that retrotransposons are causal drivers—rather than passive side-effects—of the epigenetic aging process.
- **Gerotherapeutic Repurposing:** Demonstrates that short-term treatment (12 weeks) with a safe, FDA-approved, globally available drug (Descovy) can induce profound epigenetic age deceleration.
- **Selective Intervention:** Future longevity strategies should focus on highly-targeted intracellular inhibitors like TAF to avoid systemic toxicity while preserving epigenetic youth.

The Neuro-Immune Frontier

Addressing the persistent threat of dormant neuronal viral reservoirs, cumulative neuroinflammation, and modern vaccine interventions to reduce dementia risk.

Herpes Latency & Dementia Risk

Dormant herpes virus remnants in cerebral neurons represent a lifelong, silent challenge to the brain's immune system.

- **Neuronal Latency:** Herpes Simplex Virus Type 1 (HSV-1) lies permanently quiescent inside trigeminal ganglia and cortical neurons.
- **The Indirect Trigger:** Reactivation of Varicella Zoster Virus (VZV; Shingles) causes severe neuroinflammation that acts as a molecular "alarm" to wake up latent HSV-1.
- **AD Pathology:** Active replicating HSV-1 triggers neuroinflammation (microglial activation) and prompts the accumulation of amyloid-beta and hyperphosphorylated tau as ancient antiviral defenses, leading to cognitive decline.



Shingrix Prevents Dementia Risk

17% Risk Reduction

A landmark 2024 Oxford study of 200k+ individuals in *Nature Medicine* demonstrated that the Shingrix recombinant zoster vaccine was associated with a 17% reduction in new dementia diagnoses compared to the older live vaccine (Zostavax).

5-9 Months Gained

This protection translates to an additional 5 to 9 months lived completely dementia-free. The risk-reduction benefits of Shingrix were observed across both sexes, but were found to be even more pronounced in women.

AS01B Adjuvant Effect

Beyond preventing VZV reactivation (which triggers latent HSV-1), Shingrix's AS01B adjuvant system primes and activates glial cells to facilitate the clearance of neurotoxic proteins, providing a multi-layered immunological defense.

Questions & Answers

Thank you for exploring this milestone in geroscience and retrotransposon-targeted longevity therapeutics.

gerotherapeutics@clinicalresearch.org

www.geroscience-clinicaltrials.gov

Image Sources



https://upload.wikimedia.org/wikipedia/commons/3/3a/Cell_membrane_detailed_diagram_4.svg

Source: en.wikipedia.org



https://media.easy-peasy.ai/4d66170f-c925-421e-9889-a89ac566feaa/858170e6-fd06-4179-9a3b-de7bd99b14ce_medium.webp

Source: easy-peasy.ai

https://static.vecteezy.com/system/resources/thumbnails/069/067/325/small/artistic-visualization-of-neurons-exploring-the-complex-structures-of-brain-cells-photo.jpg

Source: www.vecteezy.com